112 related articles for article (PubMed ID: 15715347)
1. [Proliferative activity of myeloma cells determined by Ki-67 antibody: biological and clinical significance].
Marković O; Marisavljević D; Cemerikić V; Vidović A; Bakrac M; Perunicić M; Suvajdzić N; Colović M
Vojnosanit Pregl; 2005 Jan; 62(1):33-8. PubMed ID: 15715347
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.
Markovic O; Marisavljevic D; Cemerikic V; Suvajdzic N; Milic N; Colovic M
Med Oncol; 2004; 21(1):73-80. PubMed ID: 15034217
[TBL] [Abstract][Full Text] [Related]
3. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance.
Marković O; Marisavljević D; Cemerikić V; Vidović A; Perunicić M; Todorović M; Elezović I; Colović M
Med Oncol; 2008; 25(4):451-7. PubMed ID: 18449811
[TBL] [Abstract][Full Text] [Related]
4. [The expression of p53 protein in patients with multiple myeloma].
Marković O; Marisavljević D; Cemerikić V; Perunicić M; Colović M
Srp Arh Celok Lek; 2007; 135(1-2):43-7. PubMed ID: 17503567
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma.
Alexandrakis MG; Passam FH; Kyriakou DS; Dambaki K; Niniraki M; Stathopoulos E
Am J Clin Oncol; 2004 Feb; 27(1):8-13. PubMed ID: 14758126
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 Immunostaining and its Correlation with Microvessel Density in Patients with Mutiple Myeloma.
Himani B; Meera S; Abhimanyu S; Usha R
Asian Pac J Cancer Prev; 2016; 17(5):2559-64. PubMed ID: 27268630
[TBL] [Abstract][Full Text] [Related]
7. The biological and clinical significance of the KI-67 growth fraction in multiple myeloma.
Drach J; Gattringer C; Glassl H; Drach D; Huber H
Hematol Oncol; 1992; 10(2):125-34. PubMed ID: 1592363
[TBL] [Abstract][Full Text] [Related]
8. [Determination proliferative activity of myeloma cells in histologic material].
Fabian P; Kren L; Nenutil R
Cesk Patol; 2004 Apr; 40(2):46-9. PubMed ID: 15233016
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
Niemöller K; Jakob C; Heider U; Zavrski I; Eucker J; Kaufmann O; Possinger K; Sezer O
J Cancer Res Clin Oncol; 2003 Apr; 129(4):234-8. PubMed ID: 12700896
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections.
Pellegrini W; Facchetti F; Marocolo D; Salvi L; Capucci A; Tironi A; Rossi G
Histopathology; 1995 Nov; 27(5):397-405. PubMed ID: 8575729
[TBL] [Abstract][Full Text] [Related]
11. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.
Alexandrakis MG; Passam FH; Dambaki C; Pappa CA; Stathopoulos EN
J Clin Pathol; 2004 Aug; 57(8):856-60. PubMed ID: 15280408
[TBL] [Abstract][Full Text] [Related]
12. Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I.
Gastinne T; Leleu X; Duhamel A; Moreau AS; Franck G; Andrieux J; Lai JL; Coiteux V; Yakoub-Agha I; Bauters F; Harousseau JL; Zandecki M; Facon T;
Eur J Haematol; 2007 Oct; 79(4):297-304. PubMed ID: 17692103
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of bone marrow histology in multiple myeloma.
Subramanian R; Basu D; Dutta TK
Indian J Cancer; 2009; 46(1):40-5. PubMed ID: 19282565
[TBL] [Abstract][Full Text] [Related]
15. Tumor load in patients with multiple myeloma: β2-microglobulin levels versus whole-body MRI.
D'Anastasi M; Notohamiprodjo M; Schmidt GP; Dürr HR; Reiser MF; Baur-Melnyk A
AJR Am J Roentgenol; 2014 Oct; 203(4):854-62. PubMed ID: 25247952
[TBL] [Abstract][Full Text] [Related]
16. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody Ki-67 as a marker of proliferative activity in monoclonal gammopathies.
Girino M; Riccardi A; Luoni R; Ucci G; Cuomo A
Acta Haematol; 1991; 85(1):26-30. PubMed ID: 2011926
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
Bhatti SS; Kumar L; Dinda AK; Dawar R
Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
[TBL] [Abstract][Full Text] [Related]
19. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum beta 2-microglobulin.
Schambeck CM; Bartl R; Höchtlen-Vollmar W; Wick M; Lamerz R; Fateh-Moghadam A
Am J Clin Pathol; 1996 Jul; 106(1):64-8. PubMed ID: 8701935
[TBL] [Abstract][Full Text] [Related]
20. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
